Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
My Humble Opinion
|
Other People's Opinion
|
| A "Must Read" Blog for Insiders. -- Wall Street Journal | A bi-weekly podcast. Listen and call-in live online or download to your iPod! |
| Also see Pharma Marketing News OpEd Pieces |
Nice Try, Daiichi!Posted: January 23, 2007FDA. officials say they "deal" with 54,000 drug promotions each year, aimed at both doctors and consumers. A couple of these promotions stood out from the rest -- a wall calendar and a dry erase board for Evoxac Capsules submitted by Daiichi Sankyo, Inc. (Daiichi) under cover of Form FDA 2253 (Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use). What exactly made these materials stand out and cause the FDA to send a barn-door-closing-after-the-cows-left warning letter to Daiichi? To find out, read today's post to Pharma Marketing Blog.
For more posts in related topic areas, see: If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
|
Special Supplement Increase Physician Access and Detailing Effectiveness
Everyone knows that pharma sales reps are less effective than they used to be. Although the pharmaceutical sales force has doubled between 1995 and 2000, the number of audited calls has only increased by 10%.
Through articles and real-world case studies this Special Supplement to Pharma Marketing News presents the collective wisdom of many marketing experts who offer solutions to the problem of decreasing sales rep effectiveness and decreasing return on the physician marketing dollar.
Order and pay for this Special Supplement now using your credit card. ONLY $29.95 Printable Order Form |